NO330918B1 - E. coli bakterie med redusert genom, fremgangsmate for fremstilling av bakterien og rekombinante proteiner - Google Patents
E. coli bakterie med redusert genom, fremgangsmate for fremstilling av bakterien og rekombinante proteiner Download PDFInfo
- Publication number
- NO330918B1 NO330918B1 NO20043465A NO20043465A NO330918B1 NO 330918 B1 NO330918 B1 NO 330918B1 NO 20043465 A NO20043465 A NO 20043465A NO 20043465 A NO20043465 A NO 20043465A NO 330918 B1 NO330918 B1 NO 330918B1
- Authority
- NO
- Norway
- Prior art keywords
- sequence
- bacterium
- genome
- dna
- deleted
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 152
- 241000894006 Bacteria Species 0.000 title claims abstract description 149
- 241000588724 Escherichia coli Species 0.000 title claims description 73
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims description 21
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 173
- 238000012217 deletion Methods 0.000 claims abstract description 130
- 230000037430 deletion Effects 0.000 claims abstract description 130
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 75
- 230000001580 bacterial effect Effects 0.000 claims abstract description 75
- 238000002744 homologous recombination Methods 0.000 claims abstract description 32
- 230000006801 homologous recombination Effects 0.000 claims abstract description 32
- 230000001965 increasing effect Effects 0.000 claims abstract description 5
- 108020004414 DNA Proteins 0.000 claims description 137
- 102000004169 proteins and genes Human genes 0.000 claims description 53
- 239000013598 vector Substances 0.000 claims description 42
- 101710163270 Nuclease Proteins 0.000 claims description 37
- 238000003780 insertion Methods 0.000 claims description 27
- 230000037431 insertion Effects 0.000 claims description 27
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 210000001322 periplasm Anatomy 0.000 claims description 24
- 102000053602 DNA Human genes 0.000 claims description 23
- 210000000349 chromosome Anatomy 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 14
- 230000002759 chromosomal effect Effects 0.000 claims description 13
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims description 10
- 231100000241 scar Toxicity 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 9
- 208000032544 Cicatrix Diseases 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 6
- 235000015097 nutrients Nutrition 0.000 claims description 6
- 230000037387 scars Effects 0.000 claims description 6
- -1 TynA Proteins 0.000 claims description 5
- 238000003306 harvesting Methods 0.000 claims description 3
- 101100281245 Bacillus subtilis (strain 168) fliY gene Proteins 0.000 claims 1
- 101100077772 Dictyostelium discoideum mppA1 gene Proteins 0.000 claims 1
- 101100330975 Escherichia coli (strain K12) dcyD gene Proteins 0.000 claims 1
- 101100012781 Escherichia coli (strain K12) fecB gene Proteins 0.000 claims 1
- 101100184722 Escherichia coli (strain K12) mppA gene Proteins 0.000 claims 1
- 101100206075 Escherichia coli (strain K12) tauA gene Proteins 0.000 claims 1
- 101100105459 Escherichia coli (strain K12) yagP gene Proteins 0.000 claims 1
- 244000292604 Salvia columbariae Species 0.000 claims 1
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 claims 1
- 235000001498 Salvia hispanica Nutrition 0.000 claims 1
- 101100439912 Staphylococcus aureus (strain Mu50 / ATCC 700699) clfA gene Proteins 0.000 claims 1
- 235000014167 chia Nutrition 0.000 claims 1
- 101150116508 plsY gene Proteins 0.000 claims 1
- 101150056277 tcyJ gene Proteins 0.000 claims 1
- 101150032291 yhcA gene Proteins 0.000 claims 1
- 230000035772 mutation Effects 0.000 abstract description 5
- 239000013065 commercial product Substances 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 description 98
- 210000004027 cell Anatomy 0.000 description 64
- 235000018102 proteins Nutrition 0.000 description 44
- 230000012010 growth Effects 0.000 description 32
- 239000012634 fragment Substances 0.000 description 31
- 239000000047 product Substances 0.000 description 30
- 238000003752 polymerase chain reaction Methods 0.000 description 25
- 230000009466 transformation Effects 0.000 description 20
- 230000006798 recombination Effects 0.000 description 19
- 238000005215 recombination Methods 0.000 description 19
- 230000010076 replication Effects 0.000 description 15
- 239000002609 medium Substances 0.000 description 14
- 239000002253 acid Substances 0.000 description 12
- 150000007513 acids Chemical class 0.000 description 11
- 229960005091 chloramphenicol Drugs 0.000 description 11
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 10
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical class C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 10
- 238000010276 construction Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 9
- 108010090127 Periplasmic Proteins Proteins 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 8
- 238000004520 electroporation Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 230000009545 invasion Effects 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- 241001646716 Escherichia coli K-12 Species 0.000 description 7
- 241000607768 Shigella Species 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000010354 integration Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 238000010361 transduction Methods 0.000 description 7
- 230000026683 transduction Effects 0.000 description 7
- 239000004099 Chlortetracycline Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 229960004475 chlortetracycline Drugs 0.000 description 6
- 235000019365 chlortetracycline Nutrition 0.000 description 6
- 230000008030 elimination Effects 0.000 description 6
- 238000003379 elimination reaction Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 241001515965 unidentified phage Species 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 5
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 5
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000002703 mutagenesis Methods 0.000 description 5
- 231100000350 mutagenesis Toxicity 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108010077805 Bacterial Proteins Proteins 0.000 description 4
- 108091029865 Exogenous DNA Proteins 0.000 description 4
- 208000031448 Genomic Instability Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000002265 Human Growth Hormone Human genes 0.000 description 4
- 108010000521 Human Growth Hormone Proteins 0.000 description 4
- 241000276498 Pollachius virens Species 0.000 description 4
- 241000607762 Shigella flexneri Species 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 210000003495 flagella Anatomy 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 241000660147 Escherichia coli str. K-12 substr. MG1655 Species 0.000 description 3
- 108091008109 Pseudogenes Proteins 0.000 description 3
- 102000057361 Pseudogenes Human genes 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 101150079601 recA gene Proteins 0.000 description 3
- 239000006152 selective media Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108010044289 DNA Restriction-Modification Enzymes Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 101150052580 dam gene Proteins 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 241000589220 Acetobacter Species 0.000 description 1
- 241000588986 Alcaligenes Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108700023313 Bacteriophage Receptors Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 241000186226 Corynebacterium glutamicum Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 108010031746 Dam methyltransferase Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000702036 Enterobacteria phage 933W Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241001522750 Escherichia coli CFT073 Species 0.000 description 1
- 241000702191 Escherichia virus P1 Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000589236 Gluconobacter Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 1
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010048581 Lysine decarboxylase Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108700011325 Modifier Genes Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000168053 Pseudomonas denitrificans (nomen rejiciendum) Species 0.000 description 1
- 101710201576 Putative membrane protein Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108091061939 Selfish DNA Proteins 0.000 description 1
- 241000147000 Shigella flexneri 2a Species 0.000 description 1
- 241001518902 Shigella flexneri 2a str. 2457T Species 0.000 description 1
- 101100179903 Shigella flexneri ipaA gene Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000319304 [Brevibacterium] flavum Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 101150008667 cadA gene Proteins 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 150000002256 galaktoses Chemical class 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 101150019881 ipaB gene Proteins 0.000 description 1
- 101150080181 ipaC gene Proteins 0.000 description 1
- 101150018167 ipaD gene Proteins 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940063149 nutropin Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 101150015375 res gene Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 229940124856 vaccine component Drugs 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 101150076562 virB gene Proteins 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/08—Reducing the nucleic acid content
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/057,582 US6989265B2 (en) | 2002-01-23 | 2002-01-23 | Bacteria with reduced genome |
| PCT/US2003/001800 WO2003070880A2 (fr) | 2002-01-23 | 2003-01-22 | Bacterie a genome reduit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20043465L NO20043465L (no) | 2004-10-22 |
| NO330918B1 true NO330918B1 (no) | 2011-08-15 |
Family
ID=22011493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20043465A NO330918B1 (no) | 2002-01-23 | 2004-08-19 | E. coli bakterie med redusert genom, fremgangsmate for fremstilling av bakterien og rekombinante proteiner |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US6989265B2 (fr) |
| EP (1) | EP1483367B1 (fr) |
| JP (2) | JP4658478B2 (fr) |
| KR (1) | KR100967592B1 (fr) |
| CN (2) | CN103540543B (fr) |
| AT (1) | ATE469230T1 (fr) |
| AU (2) | AU2003239116B8 (fr) |
| BR (2) | BRPI0307125A2 (fr) |
| CA (1) | CA2473922C (fr) |
| DE (1) | DE60332708D1 (fr) |
| HK (1) | HK1072273A1 (fr) |
| IL (2) | IL162911A0 (fr) |
| IS (1) | IS7355A (fr) |
| MX (1) | MX264365B (fr) |
| NO (1) | NO330918B1 (fr) |
| NZ (1) | NZ534010A (fr) |
| SG (1) | SG155052A1 (fr) |
| WO (1) | WO2003070880A2 (fr) |
| ZA (1) | ZA200405509B (fr) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8039243B2 (en) * | 2002-01-23 | 2011-10-18 | Wisconsin Alumni Research Foundation | Insertion sequence-free bacteria |
| US8119365B2 (en) * | 2002-01-23 | 2012-02-21 | Wisconsin Alumni Research Foundation | Insertion sequence-free bacteria |
| US6989265B2 (en) * | 2002-01-23 | 2006-01-24 | Wisconsin Alumni Research Foundation | Bacteria with reduced genome |
| US8765408B2 (en) | 2002-01-23 | 2014-07-01 | Wisconsin Alumni Research Foundation | Prophage element-free bacteria |
| US20060270043A1 (en) * | 2002-01-23 | 2006-11-30 | Blattner Frederick R | Bacteria with reduced genome |
| US7303906B2 (en) | 2002-09-06 | 2007-12-04 | Wisconsin Alumni Research Foundation | Competent bacteria |
| JP2007534320A (ja) * | 2004-02-27 | 2007-11-29 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | ポリヌクレオチド合成法 |
| WO2005087940A1 (fr) * | 2004-03-11 | 2005-09-22 | Wisconsin Alumni Research Foundation | Micro-organismes genetiquement modifies presentant un metabolisme modifie |
| KR100585450B1 (ko) * | 2004-09-02 | 2006-06-07 | 한국과학기술원 | 유전자 결실을 위한 선형 ｄｎａ 단편, 이를 이용하여생물막 형성이 억제된 대장균 변이주 및 이의 제조 방법 |
| AU2005308101A1 (en) * | 2004-11-26 | 2006-06-01 | Kyowa Hakko Kirin Co., Ltd. | Industrially useful microorganism |
| WO2007005053A1 (fr) * | 2005-06-30 | 2007-01-11 | Codon Devices, Inc. | Procédés d'assemblage hiérarchique pour l'ingénierie des génomes |
| EP1915445A2 (fr) | 2005-08-20 | 2008-04-30 | Scarab Genomics, LLC | E. coli a genome reduit |
| MX297190B (en) | 2005-09-08 | 2012-03-16 | Scarab Genomics Llc | Oxygen-regulated microorganisms |
| DE102006004871A1 (de) * | 2006-02-02 | 2007-08-09 | Wacker Chemie Ag | Mikroorganismenstamm zur Produktion von rekombinanten Proteinen |
| EP2027268B1 (fr) * | 2006-04-22 | 2010-07-07 | Scarab Genomics, LLC | PROCÉDÉS ET COMPOSITIONS PERMETTANT DE PRODUIRE DES PROTÉINES RECOMBINANTES EN UTILISANT UN GÈNE D'ARNt |
| US20100144548A1 (en) | 2006-08-03 | 2010-06-10 | Wisconsin Alumni Research Foundation | Vector systems |
| EP2344646A2 (fr) * | 2008-09-12 | 2011-07-20 | Scarab Genomics, LLC | Bactofection d'un génome propre |
| US20120093865A2 (en) | 2009-02-12 | 2012-04-19 | Scarab Genomics Llc | Compositions comprising reduced genome bacteria for use in treatment of sepsis |
| CN102666838B (zh) | 2009-11-18 | 2018-04-10 | 麦兰特公司 | 用于高效产生化学品的工程化微生物 |
| WO2011080505A2 (fr) | 2009-12-28 | 2011-07-07 | Bigdna Ltd | Procédé de culture de phage pour un usage commercial |
| US10224182B2 (en) | 2011-10-17 | 2019-03-05 | Novellus Systems, Inc. | Mechanical suppression of parasitic plasma in substrate processing chamber |
| WO2013059595A1 (fr) | 2011-10-20 | 2013-04-25 | Scarab Genomics, Llc | Bactéries à génome réduit ayant une stabilité génétique améliorée |
| EP2825663B1 (fr) | 2012-03-13 | 2019-08-07 | Board of Trustees of the University of Arkansas | Plateforme d'expression et de purification de protéines à base de séparatome |
| US9484233B2 (en) | 2012-04-13 | 2016-11-01 | Novellus Systems, Inc. | Carousel reactor for multi-station, sequential processing systems |
| EP2916854A4 (fr) * | 2012-11-06 | 2016-06-22 | Aduro Biotech Inc | Espèces bactériennes éventuellement atténuées et procédés de préparation et d'utilisation associés |
| US9449795B2 (en) | 2013-02-28 | 2016-09-20 | Novellus Systems, Inc. | Ceramic showerhead with embedded RF electrode for capacitively coupled plasma reactor |
| US11053513B2 (en) | 2013-07-15 | 2021-07-06 | Donald Danforth Plant Science Center | Enhanced oil production and stress tolerance in plants |
| WO2015042105A1 (fr) | 2013-09-17 | 2015-03-26 | Board Of Trustees Of The University Of Arkansas | Plate-forme de purification et d'expression de protéines sur la base du séparatome de e. coli |
| JP6545676B2 (ja) | 2013-11-14 | 2019-07-17 | スカラブ ゲノミクス， エルエルシー | 改善された代謝能力を有する細菌 |
| JP6473460B2 (ja) * | 2014-03-03 | 2019-02-20 | スカラブ ゲノミクス， エルエルシー | 大腸菌における組換えｃｒｍ１９７の産生強化 |
| ES2773601T3 (es) | 2014-07-22 | 2020-07-13 | Nmc Inc | Sistemas de fijación de carbono mejorados en plantas y algas |
| BR112017020916B1 (pt) | 2015-04-02 | 2022-01-25 | Scarab Genomics, Llc | Processo de fermentação contínua para a produção de produto biológico |
| AU2018329671B2 (en) | 2017-09-05 | 2023-12-07 | Scarab Genomics, Llc | Methods and compositions for improved expression of recombinant proteins |
| CN112680393B (zh) * | 2021-01-15 | 2023-04-07 | 江南大学 | 一种能提高生产效率的无菌毛大肠杆菌的构建及应用 |
| CN114410564B (zh) * | 2022-04-02 | 2022-07-19 | 中国农业大学 | 一种用于5-氨基乙酰丙酸生产的菌株及生产方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US647216A (en) | 1899-10-18 | 1900-04-10 | Charles N Perkins | Nozzle-holder. |
| DE3586386T2 (de) | 1984-10-05 | 1993-01-14 | Genentech Inc | Dna, zellkulturen und verfahren zur sekretion von heterologen proteinen und periplasmische proteinrueckgewinnung. |
| US4981797A (en) | 1985-08-08 | 1991-01-01 | Life Technologies, Inc. | Process of producing highly transformable cells and cells produced thereby |
| US4851348A (en) | 1986-07-16 | 1989-07-25 | Cold Spring Harbor Laboratory | Biologically pure escherichia coli cell line which is a deoR- mutant and which is more transformation efficient with foreign plasmids than deoR+ escherichia coli cell lines, processes for obtaining these cell lines, methods of use |
| EP0300035B1 (fr) * | 1987-01-30 | 1995-05-10 | The President And Fellows Of Harvard College | Mutants de protease periplasmique d'escherichia coli |
| JP2676511B2 (ja) | 1987-03-23 | 1997-11-17 | 株式会社日立製作所 | 酢酸を指標とした培養方法及びその装置 |
| US5578464A (en) * | 1989-10-31 | 1996-11-26 | Schering Corporation | E. coli secretory strains |
| US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| US5474896A (en) * | 1992-05-05 | 1995-12-12 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| US5747662A (en) * | 1995-03-01 | 1998-05-05 | Genentech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| EP0798380A3 (fr) * | 1996-03-28 | 1998-04-29 | Mitsui Toatsu Chemicals, Inc. | Méthode de production des protéines par sécrétion |
| FR2750704B1 (fr) * | 1996-07-04 | 1998-09-25 | Rhone Poulenc Rorer Sa | Procede de production d'adn therapeutique |
| JP2003524368A (ja) * | 1997-08-26 | 2003-08-19 | アリアド ジーン セラピューティクス インコーポレイテッド | ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白 |
| US6015709A (en) * | 1997-08-26 | 2000-01-18 | Ariad Pharmaceuticals, Inc. | Transcriptional activators, and compositions and uses related thereto |
| ES2337027T3 (es) * | 1997-12-05 | 2010-04-20 | Europaisches Laboratorium Fur Molekularbiologie (Embl) | Nuevo metodo de clonacion de dna basado en el sistema de recombinacion rece-rect de e. coli. |
| US6022952A (en) * | 1998-04-01 | 2000-02-08 | University Of Alberta | Compositions and methods for protein secretion |
| JP2000333684A (ja) * | 1999-05-26 | 2000-12-05 | Novo Nordisk As | グルコースイソメラーゼ活性を有するポリペプチド及びそれをコードする核酸 |
| AU1206801A (en) | 1999-10-13 | 2001-04-23 | University Of Georgia Research Foundation, Inc., The | High yield protein expression system and methods |
| ES2394877T3 (es) | 2000-08-14 | 2013-02-06 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Recombinación homóloga mejorada mediada por proteínas de recombinación de lambda |
| KR20050044706A (ko) | 2001-12-05 | 2005-05-12 | 디에스엠 아이피 어셋츠 비.브이. | 방향족 아미노산 대사산물 또는 이의 유도체의 생산 방법 |
| US6989265B2 (en) | 2002-01-23 | 2006-01-24 | Wisconsin Alumni Research Foundation | Bacteria with reduced genome |
| US7303906B2 (en) | 2002-09-06 | 2007-12-04 | Wisconsin Alumni Research Foundation | Competent bacteria |
| WO2005087940A1 (fr) | 2004-03-11 | 2005-09-22 | Wisconsin Alumni Research Foundation | Micro-organismes genetiquement modifies presentant un metabolisme modifie |
-
2002
- 2002-01-23 US US10/057,582 patent/US6989265B2/en not_active Expired - Lifetime
-
2003
- 2003-01-22 AU AU2003239116A patent/AU2003239116B8/en not_active Expired
- 2003-01-22 MX MXPA04006942 patent/MX264365B/es active IP Right Grant
- 2003-01-22 BR BRPI0307125A patent/BRPI0307125A2/pt active IP Right Grant
- 2003-01-22 CA CA2473922A patent/CA2473922C/fr not_active Expired - Lifetime
- 2003-01-22 NZ NZ534010A patent/NZ534010A/en not_active IP Right Cessation
- 2003-01-22 WO PCT/US2003/001800 patent/WO2003070880A2/fr active IP Right Grant
- 2003-01-22 AT AT03733830T patent/ATE469230T1/de not_active IP Right Cessation
- 2003-01-22 CN CN201310363511.5A patent/CN103540543B/zh not_active Expired - Lifetime
- 2003-01-22 CN CN03802545.0A patent/CN1620497B/zh not_active Expired - Lifetime
- 2003-01-22 DE DE60332708T patent/DE60332708D1/de not_active Expired - Lifetime
- 2003-01-22 BR BRPI0307125-1A patent/BRPI0307125B1/pt unknown
- 2003-01-22 KR KR1020047011334A patent/KR100967592B1/ko active IP Right Grant
- 2003-01-22 IL IL16291103A patent/IL162911A0/xx unknown
- 2003-01-22 JP JP2003569773A patent/JP4658478B2/ja not_active Expired - Lifetime
- 2003-01-22 EP EP03733830A patent/EP1483367B1/fr not_active Expired - Lifetime
- 2003-01-22 SG SG200702708-9A patent/SG155052A1/en unknown
-
2004
- 2004-07-12 ZA ZA2004/05509A patent/ZA200405509B/en unknown
- 2004-07-20 IS IS7355A patent/IS7355A/is unknown
- 2004-08-19 NO NO20043465A patent/NO330918B1/no not_active IP Right Cessation
-
2005
- 2005-05-13 HK HK05103985.6A patent/HK1072273A1/xx not_active IP Right Cessation
- 2005-07-01 US US11/173,900 patent/US8043842B2/en not_active Expired - Fee Related
-
2008
- 2008-06-30 AU AU2008202865A patent/AU2008202865A1/en not_active Abandoned
- 2008-11-18 IL IL195374A patent/IL195374A/en active IP Right Grant
-
2010
- 2010-09-21 JP JP2010210443A patent/JP5255030B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO330918B1 (no) | E. coli bakterie med redusert genom, fremgangsmate for fremstilling av bakterien og rekombinante proteiner | |
| EP2007871A1 (fr) | Bacterie demunie de sequence d'insertion | |
| US8039243B2 (en) | Insertion sequence-free bacteria | |
| CN103097537B (zh) | 自删除质粒 | |
| US8765408B2 (en) | Prophage element-free bacteria | |
| DK3158065T3 (en) | NUCLEIC ACIDS AND VECTORS FOR USE WITH METHANOTROPHIC BACTERIES | |
| US20050032225A1 (en) | Competent bacteria | |
| JP7312741B2 (ja) | 望ましい遺伝子発現を促進するためのプラスミドアディクションシステム | |
| CN111363714B (zh) | 一种食品级嗜热链球菌表达载体的构建方法 | |
| CN110591994B (zh) | 一种基于氢氧化钠刺激的哈维弧菌同源重组基因敲除的方法 | |
| US20060270043A1 (en) | Bacteria with reduced genome | |
| Altenbuchner et al. | Escherichia coli | |
| CN110591993A (zh) | 一种基于盐酸刺激的哈维弧菌同源重组基因敲除的方法 | |
| CN112175981B (zh) | 一种基于无水乙醇或十二烷基磺酸钠刺激的哈维弧菌定点基因敲除的方法 | |
| CN110878293B (zh) | 缺失yceD基因的地衣芽胞杆菌在异源蛋白生产中的应用 | |
| CN100513572C (zh) | 霍乱毒素b亚基的表达系统 | |
| CN116640713A (zh) | 基于fimC基因敲除的哈维弧菌高接合转移效率菌株及其构建方法和应用 | |
| CN116622755A (zh) | 一种辅助大肠杆菌自适应进化的基因编辑质粒载体、构建方法、工程菌及应用 | |
| CN116410914A (zh) | 一种发酵脱臭解淀粉芽胞杆菌工程菌及其在血红素合成中的应用 | |
| Slater et al. | Global Mutational Analysis of NtrC-Like | |
| Silver | Part Assembly |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |